Insider Trading February 19, 2026

Glenbrook Capital Raises Its Stake in SenesTech After Week of Strong Momentum

Institutional buyer accumulates 85,901 SNES shares across three trades as company advances e-commerce strategy and secures New Zealand approval for Evolve

By Ajmal Hussain SNES
Glenbrook Capital Raises Its Stake in SenesTech After Week of Strong Momentum
SNES

Glenbrook Capital Management boosted its ownership in SenesTech, Inc. (NASDAQ: SNES) via three purchases between February 17 and February 19, 2026, acquiring 85,901 shares for $200,634. The buying coincided with a 20% one-week stock gain, and comes as SenesTech shifts to direct e-commerce sales on Amazon, records e-commerce as over half of 2025 revenue, secures New Zealand approval for its Evolve fertility control product, and announces the planned retirement of CEO Joel Fruendt.

Key Points

  • Glenbrook Capital Management purchased 85,901 shares of SenesTech between Feb. 17 and Feb. 19, 2026, spending $200,634 and raising its direct holding to 704,211 shares - impacting small-cap equities and institutional ownership dynamics.
  • SenesTech is managing direct sales of Evolve Rat and Evolve Mouse on Amazon; e-commerce represented more than half of 2025 revenue - relevant to e-commerce and pest control/agribusiness sectors.
  • Evolve received regulatory approval in New Zealand from the Ministry for Primary Industries, with an initial stocking order shipped to distribution partner Evicom - affecting distribution and international market expansion considerations.

Insider buying details

Glenbrook Capital Management, identified as a 10% owner of SenesTech, Inc. (NASDAQ: SNES), increased its direct holding in the company through a series of purchases filed on Form 4 with the Securities and Exchange Commission. The firm bought a total of 85,901 common shares between February 17 and February 19, 2026, spending $200,634 in aggregate. Purchase prices ranged from $2.29 to $2.402 per share.

Transaction specifics show three discrete trades: 40,807 shares at $2.2911 on February 17; 10,481 shares at $2.29 on February 18; and 34,613 shares at $2.402 on February 19. Following these acquisitions, Glenbrook Capital Management now holds 704,211 shares of SenesTech directly.


Market context and valuation

The buying occurred as SNES experienced notable short-term momentum, with the stock producing a 20% return over the prior week, according to InvestingPro data. SenesTech trades near InvestingPro’s Fair Value estimate and carries a market capitalization reported at $12.6 million.


Operational moves: e-commerce and distribution

Separately from the ownership change, SenesTech has shifted to directly managing sales of its Evolve Rat and Evolve Mouse products on Amazon. The company described this as a move to strengthen its online presence. That emphasis on e-commerce aligns with the disclosed revenue mix: e-commerce accounted for more than half of SenesTech’s revenue in 2025.

On the regulatory and distribution front, SenesTech’s Evolve fertility control product received approval for use in New Zealand from the Ministry for Primary Industries. The approval is tied to New Zealand’s Predator Free 2050 initiative, and an initial stocking order for distribution was shipped to SenesTech’s partner, Evicom.


Leadership transition

The company also announced a planned change at the top. Joel Fruendt, SenesTech’s President and CEO, said he will retire once a successor is appointed or by June 30, 2026, whichever comes first. Fruendt has been with the company since 2022 and is credited by the company with having played a key role in the development and launch of the Evolve product.


What this means for stakeholders

The recent insider purchases, operational shifts toward direct e-commerce management, international regulatory progress, and an announced CEO transition are concurrent developments that stakeholders will likely monitor. The factual record shows increased insider accumulation by an institutional holder, a revenue mix with significant e-commerce exposure, a regulatory green light for Evolve in New Zealand with an initial shipment to a distribution partner, and a defined timetable for executive succession.

Given the company’s small market capitalization and concentrated sales channel contribution from e-commerce, investors and counterparties may continue to watch execution on online sales, distribution rollouts, and the leadership transition timeline for signs of operational continuity and market traction.

Risks

  • Leadership uncertainty: CEO Joel Fruendt will retire upon appointment of a successor or by June 30, 2026, introducing a transition period that could affect strategic continuity - impacting corporate governance and operational execution.
  • Revenue concentration: e-commerce accounted for over half of SenesTech’s 2025 revenue, which could make sales and revenue sensitive to online channel performance and platform dynamics - an operational risk for the company and e-commerce sector exposure.
  • Scale and liquidity constraints: SenesTech’s reported market capitalization of $12.6 million indicates a small-cap profile, which can imply greater stock volatility and potential liquidity limitations for investors in small-cap equities.

More from Insider Trading

Bank of the James Director Adds $20,412 in Shares; Co-Founder Retires After Long Tenure Feb 20, 2026 Rogers Corp Director Disposes of 8,000 Shares; Stock Near Yearly High After Strong Quarter Feb 20, 2026 Nicolet Bankshares Director Executes Stock Sales and Option Exercise Totaling Over $2 Million Feb 20, 2026 CME Group Director Disposes $91,770 in Shares as Company Advances New Products Feb 20, 2026 Espey MFG Director Sells $138,962 in Stock as Audit Committee Chair Changes Feb 20, 2026